[sangfroid_bio]

The problem is that the aforementioned advances tend to often be 1) Patent encumbered, 2) Difficult to scale and put into production i.e. works only under very specific conditions in the lab with very exact set of dependencies required. 3) FDA the ultimate gatekeeper. There are multiple ways to improve upon (2) but the first and last can only be changed through legislation and the biotechnology establishment is perfectly happy with the status quo (yay for regulatory capture and rentseeking). Credentialism is also a major problem, good luck raising funding without a graduate degree (or several).